oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes | NEJM Oral Semaglutide and Cardiovascular Outcomes

If significant fibrosis is confirmed, patients should be referred to a specialist to perform liver biopsy and confirm the diagnosis histologically ( Chronic inflammation is the driving force for the onset and progression of fibrosis in NASH ( 4

Results published in the New England Journal of Medicine showed that 86.4 percent of the semaglutide group lost at least 5 percent of body weight, compared to 31.5 percent of the placebo group

doi: 10.1161/01.CIR.0000091084.46500.BB 49 FilippatosTDPanagiotopoulouTVElisafMS

Compounding access may be limited for patients, particularly in areas with ambiguous regulations

There are no studies showing that taking B12 if your levels are normal will help your nails grow stronger or longer